河北省2010—2018年含麻成分疫苗补充免疫疑似预防接种异常反应监测分析

doi:10.3969/j.issn.1006-3110.2021.11.013

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (689 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的了解河北省2010—2018年含麻成分疫苗(measles-containing vaccine, MCV)补充免疫活动中疑似预防接种异常反应(adverse events following immunization, AEFI)特征,为及时妥善处置补充免疫活动中发生的不良反应提供科学依据。方法通过全国AEFI信息管理系统和各市专项上报的MCV补充免疫接种数据,对河北省2010—2018年MCV补充免疫活动中AEFI监测数据进行描述流行病学分析。结果河北省2010—2018年MCV补充免疫共报告AEFI个案2 590例,总报告发生率为64.40/10万剂;男性略多于女性,年龄主要集中在0～6岁的儿童。不良反应报告发生率为63.10/10万剂,其中,一般反应为54.03/10万剂、异常反应为9.08/10万剂。62.19%的异常反应临床诊断为过敏反应导致的皮疹。严重异常反应报告发生率为3.18/10万剂。不良反应主要发生在接种后1 d内。结论河北省2010—2018年MCV补充免疫的AEFI病例以一般反应为主。异常反应以过敏导致的皮疹类为主,严重异常反应报告发生率未见明显升高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王亚菲
	孙丽
	许晓萌
	王晶辉
	崔世恒
	郝玲
	张振国

关键词 ：含麻成分疫苗, 补充免疫, 疑似预防接种异常反应, 监测

Abstract：Objective To understand the features of adverse events following immunization (AEFI) after supplementary immunization activity of measles-containing vaccines (MCV) in Hebei Province during 2010-2018, and to provide a scientific basis for promptly and properly disposing the adverse reactions in supplementary immunization activity. Methods Based on the data from the National AEFI Information Management System and MCV supplementary immunization data specially reported by each city, a descriptive epidemiological analysis was performed on the surveillance data of AEFI after supplementary immunization activity of MCV in Hebei Province from 2010 to 2018. Results A total of 2,590 cases of AEFI after MCV supplementary immunization were reported in Hebei Province from 2010 to 2018, with a totally reported incidence rate of 64.40 per 100,000 doses. The male cases were slightly more than the female cases. Most of the AEFI cases were children aged 0-6 years. The reported incidence rate of adverse reactions was 63.10 per 100,000 doses, with a reported incidence rate of 54.03/100,000 doses for common vaccine reactions and a reported incidence rate of 9.08/100,000 doses for rare vaccine reactions. 60.19% of the rare vaccine reactions were clinically diagnosed as rashes caused by anaphylaxis. The reported incidence rate of severe vaccine reactions was 3.18/100,000 doses. The adverse reactions mainly occurred within one day after vaccination. Conclusion Most of the AEFI cases after supplementary immunization with MCV in Hebei Province during 2010-2018 were common vaccine reactions. The majority of rare vaccine reactions were clinically diagnosed as rashes caused by anaphylaxis. There was no significant increase in the reported incidence rate of severe vaccine reactions.

Key words： measles-containing vaccine supplementary immunization adverse event following immunization surveillance

收稿日期: 2020-12-30

R186

通讯作者: 张振国,E-mail:hbepi@hotmail.com。

作者简介: 王亚菲(1987-),女,河北邢台人,硕士,主要从事预防接种异常反应监测工作。

引用本文:

王亚菲, 孙丽, 许晓萌, 王晶辉, 崔世恒, 郝玲, 张振国. 河北省2010—2018年含麻成分疫苗补充免疫疑似预防接种异常反应监测分析[J]. 实用预防医学, 2021, 28(11): 1332-1335. WANG Ya-fei, SUN Li, XU Xiao-meng, WANG Jing-hui, CUI Shi-heng, HAO Ling, ZHANG Zhen-guo. Surveillance of adverse events following supplementary immunization with measles-containing vaccines in Hebei Province, 2010-2018. , 2021, 28(11): 1332-1335.

链接本文:

https://www.syyfyx.com/CN/10.3969/j.issn.1006-3110.2021.11.013 或 https://www.syyfyx.com/CN/Y2021/V28/I11/1332

[1] 王华庆,安志杰,尹遵栋. 国家免疫规划七种针对传染病70年防控成就回顾[J]. 中国疫苗和免疫, 2019, 25(4):359-367.
[2] Paules CI,Marston HD,Fauci AS. Measles in 2019-Going Backward[J]. New Engl J Med, 2019, 380(23):2185-2187.
[3] 苏琪茹,郝利新,马超,等. 中国2015—2016年麻疹流行病学特征分析[J]. 中国疫苗和免疫, 2018, 24(2):146-151.
[4] 马超,苏琪茹,郝利新,等. 中国2017—2018年麻疹流行病学特征[J]. 中国疫苗和免疫, 2020, 26(1):5-8, 41.
[5] 马超,郝利新,温宁,等. 中国2019年麻疹流行病学特征[J]. 中国疫苗和免疫, 2020, 26(5):493-497.
[6] 国家卫生和计划生育委员会. 预防接种工作规范(2016年版)[Z]. 2016-12-06.
[7] Portnoy A,Jit M,Helleringer S,et al. Comparative distributional impact of routine immunization and supplementary immunization activities in delivery of measles vaccine in low-and middle-income countries[J]. Value Health, 2020, 23(7):891-897.
[8] Chakrabarti A,Grépin KA,Helleringer S. The impact of supplementary immunization activities on routine vaccination coverage: an instrumental variable analysis in five low-income countries[J]. PLoS One, 2019, 14(2):e0212049.
[9] Chuang SK,Lau YL,Lim WL,et al. Mass measles immunization campaign: experience in the Hong Kong special administrative region of China[J]. Bull World Health Organ, 2002, 80(7):585-591.
[10] Danova J,Kocourkova A,Celko AM. Active surveillance study of adverse events following immunisation of children in the Czech Republic[J]. BMC Public Health, 2017, 17(1):167-172.
[11] 武文娣,刘大卫,李克莉,等. 中国2010年含麻疹成分疫苗强化免疫活动疑似预防接种异常反应监测分析[J]. 中国疫苗和免疫, 2012, 18(5):402-407, 455.
[12] 孙丽,王亚菲,王晶辉,等. 河北省2013—2017年疑似预防接种异常反应监测分析[J]. 实用预防医学, 2020, 27(10):1192-1198.
[13] 孙丽,张富斌,张振国,等. 2010—2012年河北省疑似预防接种异常反应监测分析[J]. 河北医药, 2014, 36(23):3646-3648.
[14] 叶家楷,李克莉,许涤沙,等. 中国2013年疑似预防接种异常反应信息管理系统数据分析[J]. 中国疫苗和免疫, 2015, 21(2):121-131, 200.
[15] 武文娣,李克莉,郑景山,等. 中国2011年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫, 2013, 19(2):97-109.
[16] 叶家楷,李克莉,许涤沙,等. 中国2015年疑似预防接种异常反应监测分析[J]. 中国疫苗和免疫, 2017, 23(5):481-492, 511.
[17] 武文娣,刘大卫,李克莉,等. 中国2010年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫, 2012, 18(5):385-397.
[18] 叶家楷,李克莉,许涤沙,等. 中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J]. 中国疫苗和免疫, 2016, 22(2):125-137.
[19] 武文娣,刘大卫,李克莉,等. 中国2012年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫, 2014, 20(1):1-12, 66.
[20] 丛艳丽,孙丽,崔世恒,等. 河北省2016年麻疹流行特征及控制策略分析[J]. 实用预防医学, 2019, 26(10):1245-1247.
[21] 丛艳丽,孙丽,张富斌,等. 2015年河北省麻疹流行特征及消除麻疹策略[J]. 职业与健康, 2017, 33(13):1853-1855.
[22] 李克莉,张丽娜,叶家楷,等. 中国2017年疑似预防接种异常反应监测[J]. 中国疫苗和免疫, 2020,26(1):9-18.
[23] World Health Organization. Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization[R].Geneva: WHO, 2019:1-30.
[24] Meng FY,Sun Y,Shen YG,et al. Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China[J]. PLoS One, 2017, 12(2):e0172108.
[25] Da Dalt L,Zerbinati C,Strafella MS,et al. Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study[J]. Ital J Pediatr, 2016, 42(1):60.
[26] World Health Organization. Mass measles immunization campaigns: reporting and investigation adverse events following immunization[R].Geneva: WHO, 2002:1-30.